Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q86WU2

UPID:
LDHD_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q86WU2; Q8IZK5

BACKGROUND:
The enzyme Probable D-lactate dehydrogenase, mitochondrial, is pivotal in metabolizing D-lactate within mitochondria, a process essential for maintaining metabolic equilibrium and cellular function. Its unique ability to process D-lactate, but not L-lactate, underscores its specificity and importance in metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the rare metabolic disorder D-lactic aciduria with gout, Probable D-lactate dehydrogenase, mitochondrial represents a significant target for drug discovery efforts. Exploring its function and mechanisms could lead to innovative treatments for related metabolic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.